[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:aggressive-b-cell-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":22,"states":23},"Aggressive B-cell Lymphoma",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06649812","Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and\u002For Refractory Aggressive B-cell Lymphoma",[11],"Phase 2","RECRUITING","2026-08-26T02:16:17.877565Z","2026-06-16T05:54:07.922088Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT01853631","Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)",[19],"Phase 1","2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.649787Z",[],[]]